Cargando…

Clinical Juvenile Arthritis Disease Activity Score proves to be a useful tool in treat-to-target therapy in juvenile idiopathic arthritis

OBJECTIVES: To assess if the Juvenile Arthritis Disease Activity Score (JADAS71) could be used to correctly identify patients with juvenile idiopathic arthritis (JIA) in need of antitumour necrosis factor therapy (anti-TNF) therapy 3 and 6 months after start of methotrexate (MTX). METHODS: Monocentr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Swart, Joost F, van Dijkhuizen, E H Pieter, Wulffraat, Nico M, de Roock, Sytze
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2018
Materias:	Clinical and Epidemiological Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5867401/ https://www.ncbi.nlm.nih.gov/pubmed/29138257 http://dx.doi.org/10.1136/annrheumdis-2017-212104

Ejemplares similares

What are the immunological consequences of long-term use of biological therapies for juvenile idiopathic arthritis?
por: Swart, Joost F, et al.
Publicado: (2013)

Bone-marrow derived mesenchymal stromal cells infusion in therapy refractory juvenile idiopathic arthritis patients
por: Swart, Joost F, et al.
Publicado: (2019)

Monitoring patients with juvenile idiopathic arthritis using health-related quality of life
por: Doeleman, Martijn J. H., et al.
Publicado: (2021)

PReS-FINAL-2147: Immunological consequences of biologicals in juvenile idiopathic arthritis
por: Swart, JF, et al.
Publicado: (2013)

Pharmacological treatment patterns in patients with juvenile idiopathic arthritis in the Netherlands: a real-world data analysis
por: Kip, Michelle M A, et al.
Publicado: (2022)

Treating juvenile idiopathic arthritis to target: what is the optimal target definition to reach all goals?
por: Schoemaker, Casper G., et al.
Publicado: (2020)

Early predictors of prognosis in juvenile idiopathic arthritis patients: a systematic literature review
por: Van Dijkhuizen, Pieter, et al.
Publicado: (2014)

The human microbiome and juvenile idiopathic arthritis
por: Verwoerd, Anouk, et al.
Publicado: (2016)

Methotrexate therapy associated with a reduced rate of new-onset uveitis in patients with biological-naïve juvenile idiopathic arthritis
por: van Straalen, Joeri W, et al.
Publicado: (2023)

Prediction of methotrexate efficacy and adverse events in patients with juvenile idiopathic arthritis: a systematic literature review
por: Van Dijkhuizen, Pieter, et al.
Publicado: (2014)

Prevalence of familial autoimmune diseases in juvenile idiopathic arthritis: results from the international Pharmachild registry
por: van Straalen, Joeri W., et al.
Publicado: (2022)

A clinical prediction model for estimating the risk of developing uveitis in patients with juvenile idiopathic arthritis
por: van Straalen, Joeri W, et al.
Publicado: (2020)

Prediction of methotrexate efficacy and adverse events in patients with juvenile idiopathic arthritis: a systematic literature review
por: van Dijkhuizen, EH Pieter, et al.
Publicado: (2014)

Validity of a three-variable Juvenile Arthritis Disease Activity Score in children with new-onset juvenile idiopathic arthritis
por: Mcerlane, Flora, et al.
Publicado: (2013)

Costs of Hospital‐Associated Care for Patients With Juvenile Idiopathic Arthritis in the Dutch Health Care System
por: Kip, Michelle M. A., et al.
Publicado: (2022)

Burden of comorbid conditions in children and young people with juvenile idiopathic arthritis: a collaborative analysis of 3 JIA registries
por: Kearsley-Fleet, Lianne, et al.
Publicado: (2021)

Increased incidence of inflammatory bowel disease on etanercept in juvenile idiopathic arthritis regardless of concomitant methotrexate use
por: van Straalen, Joeri W, et al.
Publicado: (2021)

Prediction of clinical non-response to methotrexate treatment in juvenile idiopathic arthritis
por: Van Dijkhuizen, EH Pieter, et al.
Publicado: (2011)

Prediction of clinical non-response to methotrexate treatment in juvenile idiopathic arthritis
por: Van Dijkhuizen, Pieter E H, et al.
Publicado: (2011)

The Dutch version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR)
por: Wulffraat, Nico, et al.
Publicado: (2018)

Mesenchymal stromal cells suppress synovial fluid-derived t cells from juvenile idiopathic arthritis patients in vitro
por: Wienke, J, et al.
Publicado: (2014)

Real-world comparison of the effects of etanercept and adalimumab on well-being in non-systemic juvenile idiopathic arthritis: a propensity score matched cohort study
por: van Straalen, Joeri W., et al.
Publicado: (2022)

Overlap of disease susceptibility loci for rheumatoid arthritis and juvenile idiopathic arthritis
por: Hinks, Anne, et al.
Publicado: (2010)

Consensus-based recommendations for the management of uveitis associated with juvenile idiopathic arthritis: the SHARE initiative
por: Constantin, Tamas, et al.
Publicado: (2018)

Patient’s experiences with the care for juvenile idiopathic arthritis across Europe
por: van Dijkhuizen, E. H. Pieter., et al.
Publicado: (2018)

Juvenile idiopathic arthritis patients with positive family history of autoimmune thyroid disease might benefit from serological screening: analysis of the international Pharmachild registry
por: van Straalen, Joeri W., et al.
Publicado: (2023)

Feasibility of quantitative sensory testing in juvenile idiopathic arthritis
por: Mensink, Maarten O., et al.
Publicado: (2022)

Definition and Validation of the American College of Rheumatology 2021 Juvenile Arthritis Disease Activity Score Cutoffs for Disease Activity States in Juvenile Idiopathic Arthritis
por: Trincianti, Chiara, et al.
Publicado: (2021)

The clinical and experimental treatment of Juvenile Idiopathic Arthritis
por: Nijhuis, L, et al.
Publicado: (2023)

Efficacy and safety of open-label etanercept on extended oligoarticular juvenile idiopathic arthritis, enthesitis-related arthritis and psoriatic arthritis: part 1 (week 12) of the CLIPPER study
por: Horneff, Gerd, et al.
Publicado: (2014)

Treatment to Target Using Recombinant Interleukin‐1 Receptor Antagonist as First‐Line Monotherapy in New‐Onset Systemic Juvenile Idiopathic Arthritis: Results From a Five‐Year Follow‐Up Study
por: ter Haar, Nienke M., et al.
Publicado: (2019)

Immunomodulatory actions of methotrexate on T cells in juvenile idiopathic arthritis
por: Ćalasan, Maja Bulatović, et al.
Publicado: (2012)

Prediction of Methotrexate Intolerance in Juvenile Idiopathic Arthritis: a prospective, observational cohort study
por: van Dijkhuizen, Evert Hendrik Pieter, et al.
Publicado: (2015)

Investigation of rheumatoid arthritis susceptibility loci in juvenile idiopathic arthritis confirms high degree of overlap
por: Hinks, Anne, et al.
Publicado: (2012)

PReS-FINAL-2107: In vitro investigation into mesenchymal stromal cells as a potential therapeutic in juvenile arthritis
por: Wienke, J, et al.
Publicado: (2013)

Etanercept in juvenile idiopathic arthritis: Who will benefit?
por: Otten, MH, et al.
Publicado: (2011)

Methotrexate restores effector T cell responsiveness in juvenile idiopathic arthritis
por: Bulatović, Maja, et al.
Publicado: (2011)

A three minute- screening tool for temporomandibular joint involvement in children with juvenile idiopathic arthritis
por: Giancane, Gabriella, et al.
Publicado: (2014)

Development and External Validation of a Model Predicting New‐Onset Chronic Uveitis at Different Disease Durations in Juvenile Idiopathic Arthritis
por: van Straalen, Joeri W., et al.
Publicado: (2022)

Measles, Mumps, Rubella serology in juvenile idiopathic arthritis
por: Heijstek, MW, et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_ktqvr8ve5olhpti29m66ps2ehj